U.S. Markets open in 9 hrs 1 min

Qualigen Therapeutics, Inc. (QLGN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.3400-0.2000 (-5.65%)
At close: 4:00PM EST

Qualigen Therapeutics, Inc.

2042 Corte Del Nogal
Carlsbad, CA 92011
United States
760 918 9165

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael S. PoirierChairman, CEO & PresN/AN/A1956
Mr. Christopher L. LotzVP of Fin. & CFON/AN/A1965
Mr. Shishir K. SinhaVP of OperationsN/AN/A1967
Dr. Wajdi Abdul-AhadVP of R&D and Chief Scientific OfficerN/AN/A1953
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Qualigen, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system; ALAN, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; AS1411 for treating viral-based infectious diseases; RAS-F3, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen, Inc. was founded in 1996 and is based in Carlsbad, California.

Corporate Governance

Qualigen Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.